» Articles » PMID: 28374992

Liquid Extraction Surface Analysis Mass Spectrometry Method for Identifying the Presence and Severity of Nonalcoholic Fatty Liver Disease

Overview
Journal Anal Chem
Specialty Chemistry
Date 2017 Apr 5
PMID 28374992
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The early stages of nonalcoholic fatty liver disease (NAFLD) are characterized by the accumulation of fat in the liver (steatosis). This can lead to cell injury and inflammation resulting in nonalcoholic steatohepatitis (NASH). To determine whether lipid profiling of liver tissue can identify metabolic signatures associated with disease presence and severity, we explored liquid extraction surface analysis mass spectrometry (LESA-MS) as a novel sampling tool. Using LESA-MS, lipids were extracted directly from the surface of ultrathin slices of liver tissue prior to detection by high-resolution mass spectrometry (MS). An isotopically labeled internal standard mix was incorporated into the extraction solvent to attain semiquantitative data. Data mining and multivariate statistics were employed to evaluate the generated lipid profiles and abundances. With this approach, we were able to differentiate healthy and NAFLD liver in mouse and human tissue samples, finding several triacylglyceride (TAG) and free fatty acid (FFA) species to be significantly increased. Furthermore, LESA-MS was able to successfully differentiate between simple steatosis and more severe NASH, based on a set of short-chain TAGs and FFAs. We compared the data obtained by LESA-MS to that from liquid chromatography (LC)-MS and matrix-assisted laser desorption ionization MS. Advantages of LESA-MS include rapid analysis, minimal sample preparation, and high lipid coverage. Furthermore, since tissue slices are routinely used for diagnostics in clinical settings, LESA-MS is ideally placed to complement traditional histology. Overall LESA-MS is found to be a robust, fast, and discriminating approach for determining NAFLD presence and severity in clinical samples.

Citing Articles

Mass Spectrometry Imaging of Cholesterol and Oxysterols.

Griffiths W, Yutuc E, Wang Y Adv Exp Med Biol. 2023; 1440:73-87.

PMID: 38036876 DOI: 10.1007/978-3-031-43883-7_5.


Metabolic alterations in dairy cattle with lameness revealed by untargeted metabolomics of dried milk spots using direct infusion-tandem mass spectrometry and the triangulation of multiple machine learning models.

He W, Cardoso A, Hyde R, Green M, Scurr D, Griffiths R Analyst. 2022; 147(23):5537-5545.

PMID: 36341756 PMC: 9678129. DOI: 10.1039/d2an01520j.


Spatially Mapping the Baseline and Bisphenol-A Exposed Lipidome Using Desorption Electrospray Ionization-Mass Spectrometry.

Smith M, Weber R, Viant M Metabolites. 2022; 12(1).

PMID: 35050155 PMC: 8781255. DOI: 10.3390/metabo12010033.


Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico.

Flores Y, Amoon A, Su B, Velazquez-Cruz R, Ramirez-Palacios P, Salmeron J Lipids Health Dis. 2021; 20(1):136.

PMID: 34629052 PMC: 8504048. DOI: 10.1186/s12944-021-01526-5.


Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine.

Hu Y, Wang Z, Liu L, Zhu J, Zhang D, Xu M Chem Sci. 2021; 12(23):7993-8009.

PMID: 34257858 PMC: 8230026. DOI: 10.1039/d1sc00271f.